At a glance
ClinicalIndex Comparison RecordN/ACompleted· 897 enrolled
Drug / intervention
genomic testing of T790M mutationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of T790M Mutation Testing in Patient Tissue and Blood With Various Detection Platforms at Hospital Laboratories in Comparison With Central Testing
In Brief
An observational study evaluating genomic testing of T790M mutation for Locally Advanced or Metastatic EGFR(+) NSCLC Patients. Completed, enrolled 897 participants across 31 sites.
Detailed Summary
The study primary objective is to assess the concordance of T790M resistance mutation testing from hospital-based laboratories with T790M resistance mutation testing from a central laboratory.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedDec 13, 2016
Enrollment StartJan 16, 2017
Primary CompletionJun 29, 2018
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 9.5 years ago
Interventions
genomic testing of T790M mutationprocedure
patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.